Brief: Novozymes A/S Says Novonesis Expects 6-9% Sales Cagr, 39% EBITDA Margin By 2030
20/08/2025 16:52
Aug 20 (Reuters) - Novozymes A/S NSISb.CO: NOVOZYMES A/S - NOVONESIS EXPECTS 6-9% SALES CAGR, 39% EBITDA MARGIN BY 2030 Source text: ID:nGNE7NBfvD Further company coverage: [NSISb.CO] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novozymes A/S
See all newsGivaudan jumps on fragrance outperformance; peers follow
Europe Research Roundup: IWG, Londonmetric, Sartorius
Brief: Novonesis To Build Next Generation Enzyme Production Facility In India
Next cycle in ingredient makers sector belongs to biotech, Jefferies says
Europe Research Roundup: DSM-Firmenich, Merck, Orsted